Literature DB >> 2365568

Humoral autoimmune response against S-antigen and IRBP in ocular onchocerciasis.

A Van der Lelij1, G Doekes, B S Hwan, J C Vetter, E Rietveld, J S Stilma, A Kijlstra.   

Abstract

Autoimmune mechanisms are thought to play a role in the pathogenesis of the chorioretinal changes in ocular onchocerciasis. In this study, the involvement of autoimmunity against retinal antigens in developing chorioretinitis was investigated. Serum levels of autoantibodies, directed against human S-antigen and interphotoreceptor retinoid-binding protein (IRBP), were determined in patients with onchocerciasis (n = 46) and endemic controls (n = 38) from Sierra Leone with the use of an enzyme immunoassay. In both groups high levels of anti-human S-antigen and IRBP antibodies were detected. No relationship could be demonstrated between the antiretinal antibody level and the occurrence of chorioretinitis in onchocerciasis. The levels of both anti-human S-antigen and IRBP antibodies were significantly higher in patients with onchocerciasis compared with endemic controls (P less than 0.001). Cross-reactivity of antiretinal antibodies with parasitic antigens could not be demonstrated as a possible explanation for the higher levels in patients with onchocerciasis. No correlation was found between the levels of antibodies of different classes against the crude Onchocerca volvulus, the egg antigen, or the microfilariae and the antiretinal antibody levels. Furthermore, in a panel of 13 different monoclonal antibodies directed against O. volvulus, only one showed a slight anti-human IRBP reactivity and none reacted with S-antigen. The immune response against the two retinal antigens investigated was not specific for onchocerciasis because high antibody levels were also found in patients with Bancroftian filariasis from Papua, New Guinea, and Surinam.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2365568

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

1.  Human antiretinal antibodies in toxoplasma retinochoroiditis.

Authors:  R M Whittle; G R Wallace; R A Whiston; D C Dumonde; M R Stanford
Journal:  Br J Ophthalmol       Date:  1998-09       Impact factor: 4.638

2.  Analysis of the uveitogenic determinant in repeat structure of retinal interphotoreceptor retinoid-binding protein (IRBP).

Authors:  H Inoue; M Takeuchi; T Tanaka; M Usui; S Ando; O Taguchi
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

3.  Aetiology of uveitis in Sierra Leone, west Africa.

Authors:  M J Ronday; J S Stilma; R F Barbe; W J McElroy; L Luyendijk; A H Kolk; M Bakker; A Kijlstra; A Rothova
Journal:  Br J Ophthalmol       Date:  1996-11       Impact factor: 4.638

Review 4.  Points of action in the campaign against blindness in developing countries.

Authors:  J S Stilma; S Franken; M Hogeweg; P Hardus
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

5.  Ocular onchocerciasis: current management and future prospects.

Authors:  Olufemi Emmanuel Babalola
Journal:  Clin Ophthalmol       Date:  2011-10-13

6.  Molecular and immunological characterization of hr44, a human ocular component immunologically cross-reactive with antigen Ov39 of Onchocerca volvulus.

Authors:  G Braun; N M McKechnie; W Gürr
Journal:  J Exp Med       Date:  1995-10-01       Impact factor: 14.307

7.  Immunological crossreactivity between a cloned antigen of Onchocerca volvulus and a component of the retinal pigment epithelium.

Authors:  G Braun; N M McKechnie; V Connor; C E Gilbert; F Engelbrecht; J A Whitworth; D W Taylor
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

Review 8.  Update on pathology of ocular parasitic disease.

Authors:  Dipankar Das; Varsha Ramachandra; Saidul Islam; Harsha Bhattacharjee; Jyotirmay Biswas; Akanksha Koul; Panna Deka; Apurba Deka
Journal:  Indian J Ophthalmol       Date:  2016-11       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.